Press Releases

06.02.2022

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®

06.01.2022

Pfizer Provides Update on Ownership Interest in Haleon

05.31.2022

Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability

05.26.2022

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

05.25.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

05.25.2022

Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries

05.24.2022

Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis

05.23.2022

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

05.17.2022

Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age

05.13.2022

Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission

05.10.2022

Pfizer to Acquire Biohaven Pharmaceuticals

05.06.2022

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis